Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

Presentation TCT 2016

Case Resolution: What Was Done

Presenter: John A. Bittl, David J. Maron, Kishore J. Harjai

November 01, 2016

Presentation TCT 2016

When Equipoise Exists: Is Unbiased, Informed Consent Possible?

Presenter: John A. Bittl, David J. Maron, John A. Spertus

November 01, 2016

Presentation TCT 2016

The Case for Multivessel PCI

Presenter: John A. Bittl, David J. Maron, Sripal Bangalore

November 01, 2016

Presentation TCT 2016

The Case for CABG

Presenter: John A. Bittl, David J. Maron, A. Pieter Kappetein

November 01, 2016

Presentation TCT 2016

The Case for a Trial of Medical Therapy

Presenter: John A. Bittl, David J. Maron, Michael E. Farkouh

November 01, 2016

Presentation TCT 2016

Case Presentation: Diabetes, Comorbidities, and Multivessel Disease

Presenter: John A. Bittl, David J. Maron, Kishore J. Harjai

November 01, 2016

News Daily News

Review Touts Benefits of Statins, Seeks to Dispel Safety Concerns

Todd Neale

September 12, 2016

Presentation TCT 2015

Optimal Pharmacology in the Diabetic: What's Here? What's New? What's in the Pipeline?

Presenter: Frederick Feit, David J. Maron, Norman E. Lepor

October 15, 2015

Presentation TCT 2015

Do Contemporary DES Change the Equation for PCI vs CABG in the Diabetic Patient?

Presenter: Frederick Feit, David J. Maron, Sripal Bangalore

October 15, 2015

Presentation TCT 2015

Pros and Cons of CABG vs PCI in the Diabetic Patient With Multivessel Disease: Insights From Randomized Trials

Presenter: Frederick Feit, David J. Maron, Michael E. Farkouh

October 15, 2015

Presentation TCT 2015

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Presenter: Bernard J. Gersh, Stephen D. Wiviott, David J. Maron

October 13, 2015

Presentation TCT 2015

Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? The Data Says Not as a First-Line Therapy!

Presenter: Kevin J. Beatt, Craig R. Smith, David J. Maron

October 11, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Daily News

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

Yael L. Maxwell

August 12, 2015

News Daily News

BARI 2D：改善 2 型糖尿病患者的危险因素控制情况可以提高其生存率

Yael L. Maxwell

August 12, 2015

Presentation TCT 2014

The Case for Medical Therapy without Revascularization in Most Patients with and without Diabetes

Presenter: George D. Dangas, Michael E. Farkouh, David J. Maron

September 16, 2014

Presentation TCT 2014

Wheres the Data for Any of This? Medical Therapy First Is Most Appropriate!

Presenter: Ajay J. Kirtane, David Taggart, David J. Maron

September 15, 2014

Presentation TCT 2013

The Decision to Revascularize Must Be Made on the Background of Improving Medical Therapies and Life Style Modification, with Greater Longevity

Presenter: David Maron

October 29, 2013

Presentation TCT 2013

Risk/Benefit Favors: Medical Therapy First

Presenter: David Maron

October 28, 2013

Presentation TCT 2013

Rationale, Design and Status of the ISCHEMIA Trial

Presenter: David Maron

October 28, 2013

Advertisement

Case Resolution: What Was Done

When Equipoise Exists: Is Unbiased, Informed Consent Possible?

The Case for Multivessel PCI

The Case for CABG

The Case for a Trial of Medical Therapy

Case Presentation: Diabetes, Comorbidities, and Multivessel Disease

Review Touts Benefits of Statins, Seeks to Dispel Safety Concerns

Optimal Pharmacology in the Diabetic: What's Here? What's New? What's in the Pipeline?

Do Contemporary DES Change the Equation for PCI vs CABG in the Diabetic Patient?

Pros and Cons of CABG vs PCI in the Diabetic Patient With Multivessel Disease: Insights From Randomized Trials

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? The Data Says Not as a First-Line Therapy!

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

BARI 2D：改善 2 型糖尿病患者的危险因素控制情况可以提高其生存率

The Case for Medical Therapy without Revascularization in Most Patients with and without Diabetes

Wheres the Data for Any of This? Medical Therapy First Is Most Appropriate!

The Decision to Revascularize Must Be Made on the Background of Improving Medical Therapies and Life Style Modification, with Greater Longevity

Risk/Benefit Favors: Medical Therapy First

Rationale, Design and Status of the ISCHEMIA Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content